XML 64 R55.htm IDEA: XBRL DOCUMENT v3.22.2
Earnings per Share (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
USD ($)
$ / shares
shares
Jun. 30, 2021
USD ($)
$ / shares
shares
Jun. 30, 2022
USD ($)
$ / shares
shares
Jun. 30, 2021
USD ($)
$ / shares
shares
Earnings per Class A ordinary share:        
Common stock exchange ratio 1   1  
Numerator        
Net income $ 491,597 $ 806,755 $ 619,680 $ 965,734
Less: net income attributable to non-controlling interest 187,093 365,979 263,415 455,839
Net income attributable to Royalty Pharma plc - basic 304,504 440,776 356,265 509,895
Add: Reallocation of net income attributable to non-controlling interest from the assumed conversion of Class B ordinary shares 119,224 212,961 139,886 251,506
Net income attributable to Royalty Pharma plc - diluted $ 423,728 $ 653,737 $ 496,151 $ 761,401
Denominator        
Weighted average Class A ordinary shares outstanding - basic (in shares) | shares 436,318 409,344 435,144 399,606
Class B ordinary shares exchangeable for Class A ordinary shares (in shares) | shares 170,864 197,773 172,035 207,508
Unvested RSUs (in shares) | shares 32 46 28 37
Weighted average Class A ordinary shares outstanding - diluted (in shares) | shares 607,214 607,163 607,207 607,151
Earnings per Class A ordinary share - basic (in dollars per share) | $ / shares $ 0.70 $ 1.08 $ 0.82 $ 1.28
Earnings per Class A ordinary share - diluted (in dollars per share) | $ / shares $ 0.70 $ 1.08 $ 0.82 $ 1.25
Class B Holders        
Numerator        
Less: net income attributable to non-controlling interest $ 119,224 $ 212,961 $ 139,886 $ 251,506
Legacy Investors Partnerships and RPSFT        
Numerator        
Less: net income attributable to non-controlling interest $ 67,869 $ 153,018 $ 123,529 $ 204,333